Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study
Abstract Objectives This noninterventional, multidatabase, analytical cohort study explored whether vildagliptin is associated with an increased risk of specific safety events of interest, namely angioedema, foot ulcers, or skin lesions, adverse hepatic events, or serious infections compared with ot...
Main Authors: | Rachael Williams, Wolfgang Kothny, Carmen Serban, Sandra Lopez‐Leon, Frank de Vries, Raymond Schlienger |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-07-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Subjects: | |
Online Access: | https://doi.org/10.1002/edm2.84 |
Similar Items
-
Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01) -
Bullous Pemphigoid Induced by Vildagliptin
by: Bengür Taşkıran Bahattin, et al.
Published: (2016-12-01) -
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
by: Schweizer A, et al.
Published: (2011-02-01) -
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Jong Ho Kim, et al.
Published: (2016-04-01) -
Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)